Efficacy of benralizumab in severe eosinophilic asthma: an interim analysis of a real clinical practice prospective study BEST in Russia
D. S. Fomina,
G. L. Ignatova,
T. G. Kabanova,
A. A. Kameleva,
L. S. Kozyreva,
N. I. Kosyakova,
L. M. Kudelya,
N. A. Kuzubova,
I. V. Leshсhenko,
O. A. Mukhina,
L. V. Shulzhenko https://doi.org/10.18093/0869-0189-2023-33-3-374-385
Abstract
Systematizing clinical experience in the use of biological treatments in patients with severe bronchial asthma in real world settings with assessment of clinical outcomes and quality of life level is of great interest and value in practical pulmonology.
The aim of the BEST study (Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia) was to evaluate effectiveness of benralizumab by control and quality of life associated with respiratory status in patients with eosinophilic phenotype of severe asthma in real clinical practice in Russia.
Results. The results obtained through 16 weeks of benralizumab therapy in patients with severe eosinophilic asthma (SEA) were analyzed. All 59 enrolled patients showed significant improvement in the asthma control questionnaire (ACQ-5) score, the quality of life associated with respiratory status according to the St. George Respiratory Questionnaire (SGRQ), and subjective assessments of the well-being of patients and the disease severity (PGIC and PGIS). Treatment with benralizumab contributed to a reduction in the oral glucocorticosteroids intake throughout the study period.
Conclusion. In real clinical practice, treatment with benralizumab results in significant improvement in disease control and the quality of life in patients with severe eosinophilic asthma and is characterized by a favorable safety profile.
Keywords
Supporting agencies: The article was published with the support of AstraZeneca Pharmaceuticals LLC. AstraZeneca provided funding for the scientific research, but not the drug products. The representatives of the sponsor did not participate in the writing of this article and are not responsible for the content of the article and any possible financial or other agreements with any third parties related to this article. The opinion of the sponsor’s representatives may differ from the opinion of the authors of the article and the editorial board
About the Authors
D. S. Fomina
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); State Budgetary Healthcare Institution of Moscow City “Moscow City Clinical Hospital 52”, Moscow Department of Health; Non-profit Joint Stock Company “Astana Medical University”, Ministry of Health of the Republic of Kazakhstan
Russian Federation
Competing Interests:
Russian Federation
Daria S. Fomina - Candidate of Medicine, Associate Professor, Allergist-immunologist, Associate Professor, Department of Clinical Allergology аnd Immunology, I.M. Sechenov First Moscow SMU (Sechenov University); Head of Moscow City Scientific and Practical Center of Allergology and Immunology, State Budgetary Healthcare Institution of Moscow City “Moscow City Clinical Hospital 52”,; Professor, Non-profit Joint Stock Company “Astana Medical University.
Ul. Trubetskaya 8, build. 2, Moscow, 119991; ul. Pekhotnaya 3, Moscow, 123182; ul. Beibitshilik 49a, Astana, 010000; tel.: (499) 196-19-54
Competing Interests:
The authors declare no conflict of interest
G. L. Ignatova
Federal State Budgetary Educational Institution of Higher Education “South Ural State Medical University”, Ministry of Healthcare of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Galina L. Ignatova - Doctor of Medicine, Professor, Head of Department of Therapy, Institute of Postgraduate Physician Training, South Ural State Medical University; Chief Freelance Pulmonologist of the Ural Federal District.
Ul. Vorovskogo 64, Chelyabinsk, 454092; tel.: (951) 238-20-71
Competing Interests:
The authors declare no conflict of interest
T. G. Kabanova
State Budgetary Health Institution of the Moscow Region “Moscow Regional Research Clinical Institute named after M.F. Vladimirsky”
Russian Federation
Competing Interests:
Russian Federation
Tatiana G. Kabanova - Candidate of Medicine, Head of Multidisciplinary Day Hospital.
Ul. Shchepkina 61/2, Moscow, 129110; tel.: (903) 273-18-88
Competing Interests:
The authors declare no conflict of interest
A. A. Kameleva
State Budgetary Healthcare Institution of the City of Moscow “City Clinical Hospital named after D.D. Pletnev of Moscow Department of Health”
Russian Federation
Competing Interests:
Russian Federation
Anastasia A. Kameleva, Candidate of Medicine, Allergologist-Immunologist City Clinical Hospital named after D.D. Pletnev.
Ul. Odinnadtsataya Parkovaya 32, Moscow, 105077; tel.: (916) 854-53-93
Competing Interests:
The authors declare no conflict of interest
L. S. Kozyreva
Federal State Budgetary Educational Institution of Higher Education “Bashkir State Medical University”, Ministry of Healthcare of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Liliya S. Kozyreva - Candidate of Medicine, Associate Professor, Department of Therapy and General Medical Practice with a Geriatrics Course, Institute of Additional Professional Education, Head of the Department of Pulmonology at the Clinic, Bashkir SMU, Ministry of Healthcare of Russian Federation; Chief Freelance Pulmonologist, Ministry of Health of the Republic of Bashkortostan.
Ul. Lenina 3, Ufa, Republic of Bashkortostan, 450000; tel.: (917) 414-22-96
Competing Interests:
The authors declare no conflict of interest
N. I. Kosyakova
Federal State Budgetary Institution of Science, Federal Research Center “Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences”, Ministry of Science and Higher Education of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Ninel I. Kosyakova - Doctor of Medicine, Deputy Chief Physician for Science, Head of the Department of Immunology and Allergology of the Hospital, Federal State Budgetary Institution of Science, Pushchino Scientific Center for Biological Research of the RAS.
Prospekt Nauki 3, Moscow Region, Pushchino, 142290; tel.: (916) 469-69-19
Competing Interests:
The authors declare no conflict of interest
L. M. Kudelya
Federal State Budgetary Educational Institution of Higher Education “Novosibirsk State Medical University”, Ministry of Healthcare of Russian Federation; State Budgetary Healthcare Institution of the Novosibirsk region “State Novosibirsk Regional Clinical Hospital”
Russian Federation
Competing Interests:
Russian Federation
Lyubov M. Kudelya - Doctor of Medicine, Professor, Department of Internal Diseases named after Academician L.D. Sidorova, Novosibirsk SMU, Healthcare Ministry of Russia, Head оf Pulmonology Department, State Novosibirsk Regional Clinical Hospital; Chief Pulmonologist of the Novosibirsk region.
Krasny Prospekt 52, Novosibirsk, 630091; ul. Nemirovicha-Danchenko 130, Novosibirsk, 630087; tel.: (383) 315-97-07
Competing Interests:
The authors declare no conflict of interest
N. A. Kuzubova
Federal State Budgetary Educational Institution of Higher Education “Academician I.P. Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Nataliya A. Kuzubova, Doctor of Medicine, Deputy Director for Research, Research Institute of Pulmonology, Academician I.P. Pavlov First St. Petersburg SMU.
Ul. L`va Tolstogo 6 – 8, Saint-Petersburg, 197022; tel.: (812) 338-66-06
Competing Interests:
The authors declare no conflict of interest
I. V. Leshсhenko
Federal State Budget Educational Institution of Higher Education “Ural State Medical University” of the Ministry of Health of the Russian Federation; Ural Research Institute of Phthisiopulmonology – a Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia; Limited Liability Company “Novaya bol’nitsa” Clinical Association
Russian Federation
Competing Interests:
Russian Federation
Igor V. Leshсhenko - Doctor of Medicine, Professor, Department of Phthisiology and Pulmonology, Ural SMU; Chief Researcher, Ural Research Institute of Phthisiopulmonology – A Branch of NMRCr for Phthisiology, Pulmonology and Infectious Diseases; Scientific Director, Novaya bol’nitsa” Clinical Association; Chief Freelance Pulmonologist, Healthcare Ministry of the Sverdlovsk Region.
Ul. Repina 3, Ekaterinburg, 620028; ul. 22-go Parts’ezda 50, Ekaterinburg, 620039; ul. Zavodskaya 29, Ekaterinburg, 620109; tel.: (343) 246-44-75
Competing Interests:
The authors declare no conflict of interest
O. A. Mukhina
Non-profit Joint Stock Company “Astana Medical University”, Ministry of Health of the Republic of Kazakhstan
Russian Federation
Competing Interests:
Russian Federation
Olga A. Mukhina - Allergist-Immunologist, Consultative and Diagnostic Department, Moscow City Scientific and Practical Center of Allergology and Immunology, Moscow City Clinical Hospital 52.
Ul. Pekhotnaya 3, Moscow, 123182; tel.: (499) 196-45-65
Competing Interests:
The authors declare no conflict of interest
L. V. Shulzhenko
Federal State Budgetary Educational Institution of Higher Education “Kuban State Medical University” of the Ministry of Health of the Russian Federation; Federal Budgetary Healthcare Institution “Research Institute – Regional Hospital No.1. Named after S.V. Ochapovskiy”
Russian Federation
Competing Interests:
Russian Federation
Larisa V. Shulzhenko - Doctor of Medicine, Professor, Head of Department of Pulmonology, Faculty of Postgraduate Physician Training, Kuban SMU, Head of the Department of Pulmonology, Research Institute – Regional Hospital No.1 Named after S.V. Ochapovskiy.
Ul. Mitrofana Sedina 4, Krasnodar, 350063; ul. Pervogo Maya 167, Krasnodar, 360086; tel.: (861) 252-73-38
Competing Interests:
The authors declare no conflict of interest
References
1. Global Initiative for Asthma. 2022 GINA main report. 2022 GINA Report, Global Strategy for Asthma Management and Prevention. Available at: https://ginasthma.org/gina-reports/ [Accessed: April 10, 2023].
2. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 963–974. DOI: 10.2147/COPD.S67283.
3. Price D., Wilson A.M., Chisholm A. et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J. Asthma Allergy. 2016; 9: 1–12. DOI: 10.2147/JAA.S97973.
4. Hillas G., Fouka E., Papaioannou A.I. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Rev. Respir. Med. 2020; 14 (4): 353–365. DOI: 10.1080/17476348.2020.1718495.
5. Hekking P.P.W., Wener R.R., Amelink M. et al. The prevalence of severe refractory asthma. J. Allergy Clin. Immunol. 2015; 135 (4): 896–902. DOI: 10.1016/j.jaci.2014.08.042.
6. Menzies-Gow A., Hoyte F.L., Price D.B. et al. Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab. Adv. Ther. 2022; 39 (5): 2065–2084. DOI: 10.1007/s12325-022-02098-1.
7. Menzies-Gow A., Bafadhel M., Busse W.W. et al. An expert consensus framework for asthma remission as a treatment goal. J. Allergy Clin. Immunol. 2020; 145 (3): 757–765. DOI: 10.1016/j.jaci.2019.12.006.
8. Sergeenko D.F. [Targeted therapy for asthma: precision strike]. Prakticheskaya pul’monologiya. 2022; (2): 11–15. DOI: 10.24412/2409-6636-2022-12938 (in Russian).
9. Zyryanov S.K., Butranova O.I. [Genetically engineered drugs for treatment of bronchial asthma: recent achievements]. Pul’monologiya. 2018; 28 (5): 584–601. DOI: 10.18093/0869-0189-2018-28-5-584-601 (in Russian).
10. Nenasheva N.M., Kurbacheva O.M., Avdeev S.N. et al. [Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype]. Pul’monologiya. 2020; 30 (2): 227–244. DOI: 10.18093/0869-0189-2020-30-2-227-244 (in Russian).
11. Titova O.N., Kuzubova N.A., Sklyarova D.B., Petrova M.A. [The effectiveness of benralizumab in the treatment of the eosinophilic phenotype of severe asthma in real clinical practice]. Pul’monologiya. 2021; 31 (5): 628–634. DOI: 10.18093/0869-0189-2021-31-5-628-634 (in Russian).
12. Bakakos A., Rovina N., Bakakos P. Treatment challenges in severe eosinophilic asthma: differential response to Anti-IL-5 and Anti-IL-5R therapy. Int. J. Mol. Sci. 2021; 22 (8): 3969. DOI: 10.3390/ijms22083969.
13. Tan L.D., Bratt J.M., Godor D. et al. Benralizumab: a unique IL-5 inhibitor for severe asthma. J. Asthma Allergy. 2016; 9: 71–81. DOI: 10.2147/JAA.S78049.
14. Bleecker E.R., FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115–2127. DOI: 10.1016/S0140-6736(16)31324-1.
15. FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128–2141. DOI: 10.1016/S0140-6736(16)31322-8.
16. Jones P.W., Quirk F.H., Baveystock C.M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am. Rev. Respir. Dis. 1992; 145 (6): 1321–1327. DOI: 10.1164/ajrccm/145.6.1321.
17. Byrom B., Breedon P., Tulkki-Wilke R., Platko J. Meaningful change: Defining the interpretability of changes in endpoints derived from interactive and mHealth technologies in healthcare and clinical research. J. Rehabil. Assist. Technol. Eng. 2020; 7: 2055668319892778. DOI: 10.1177/2055668319892778.
18. Kavanagh J.E., Hearn A.P., Dhariwal J. et al. Real-world effectiveness of Benralizumab in severe eosinophilic asthma. Chest. 2021; 159 (2): 496–506. DOI: 10.1016/j.chest.2020.08.2083.
19. Padilla-Galo A., Levy-Abitbol R., Olveira C. et al. Real-life experience with benralizumab during 6 months. BMC Pulm. Med. 2020; 20 (1): 184. DOI: 10.1186/s12890-020-01220-9.
20. Jackson D.J., Burhan H., Menzies-Gow A. et al. Benralizumab effectiveness in severe asthma is independent of previous biologic use. J. Allergy Clin. Immunol. Pract. 2022; 10 (6): 1534–1544.e4. DOI: 10.1016/j.jaip.2022.02.014.
21. Sereda V.P., Svirido D.A., Komarov M.V. et al. [Experience of using benralizumab in the treatment of patients with severe asthma in the clinical practice of pulmonologists in Saint-Petersburg]. Pul’monologiya. 2022; 32 (5): 670–677. DOI: 10.18093/0869-0189-2022-32-5-670-677 (in Russian).
22. Avdeev S.N., Emelyanov A.V., Kurbacheva O.M. et al. [A new delivery device for benralizumab (autoinjector, pen-injector device) in the clinical practice of treating severe eosinophilic asthma: Conclusion of the Expert Council]. Pul’monologiya. 2021; 31 (6): 776–781. DOI: 10.18093/0869-0189-2021-31-6-776-781 (in Russian).
Review
For citations:
Fomina D.S., Ignatova G.L., Kabanova T.G., Kameleva A.A., Kozyreva L.S., Kosyakova N.I., Kudelya L.M., Kuzubova N.A., Leshсhenko I.V., Mukhina O.A., Shulzhenko L.V. Efficacy of benralizumab in severe eosinophilic asthma: an interim analysis of a real clinical practice prospective study BEST in Russia. PULMONOLOGIYA. 2023;33(3):374-385. (In Russ.) https://doi.org/10.18093/0869-0189-2023-33-3-374-385
Views:
693
Email this article 